Source: International Congress 2019 – Treatment of lung cancer
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
C. Cramer - van der Welle (Utrecht, Netherlands), F. Schramel (Utrecht/Nieuwegein, Netherlands), B. Peters (Utrecht/Nieuwegein, Netherlands), O. Klungel (Utrecht, Netherlands), H. Groen (Groningen, Netherlands), E. Van De Garde (Utrecht, Netherlands). Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in extensive disease small cell lung cancer (ED SCLC). 375

Member's Comments

No comment yet.

Related content which might interest you: Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer (ED SCLC) Source: International Congress 2019 – Treatment of lung cancer Year: 2019 Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer Source: Eur Respir J, 52 (6) 1801100; 10.1183/13993003.01100-2018 Year: 2018 Treatment of extensive-stage small cell lung carcinoma: current status and future prospects Source: Eur Respir J 2010; 35: 202-215 Year: 2010 Challenges in the management of SCLC Part 2: Extensive disease, prophylaxis/treatment of brain metastases Source: ERS webinar 2021: Challenges in the management of SCLC Part 2: Extensive disease, prophylaxis/treatment of brain metastases Year: 2021 Managing the initial treatment and multiple relapses in a small cell lung cancer patient with limited disease Source: International Congress 2018 – CC3 Lung cancer: personalised treatment and palliative care Year: 2018 Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009 European treatment guidelines: small cell lung cancer (SCLC) Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Lung cancer: does age affect treatment strategy? Source: Eur Respir Mon; 2009: 43:306–326 Year: 2009 Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Surgery for non small cell lung cancer (NSCLC) and functional limits: is there a possible beneficial role of preoperative pulmonary rehabilitation? Source: Eur Respir J 2004; 24: Suppl. 48, 522s Year: 2004 Systematic review of the effect of chemotherapy on quality of life (QoL) and symptom control in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 New cryobiopsy techniques influence the rate of diagnosis small cell lung cancer (SCLC) Source: Annual Congress 2010 - The role of endoscopy in the diagnosis of lung cancer Year: 2010 Systemic treatment of small cell lung cancer Source: Annual Congress 2008 - PG6 - Thoracic oncology: new treatments for thoracic malignancies (other than nonsmall cell lung cancer) Year: 2008 Clinical course of asymptomatic small enhancing brain nodules in patients with nonsmall cell lung cancer: do we have to follow them up? Source: ERJ Open Res, 6 (3) 00109-2020; 10.1183/23120541.00109-2020 Year: 2020 Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC) Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Reflex testing  is crucial for treatment decisions in advanced non small cell lung cancer (NSCLC) Source: International Congress 2017 – Chinese Programme 2017 Year: 2017 Treatment of limited disease small cell lung cancer: the multidisciplinary team Source: Eur Respir J, 50 (2) 1700422; 10.1183/13993003.00422-2017 Year: 2017 Update on small cell lung cancer management Source: Breathe 2012; 8: 315-330 Year: 2012